Amid a yearslong wave of enthusiasm and uptake for Eli Lilly and Novo Nordisk's blockbuster obesity medicines, the drugs have scored a strong endorsement from an independent U.S. cost watchdog. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results